Duloxetine and Reboxetine Combination

The combination of duloxetine and reboxetine represents a therapeutic approach used primarily in the treatment of depression, particularly for patients who have not responded adequately to duloxetine monotherapy. This combination pairs two different antidepressant mechanisms - duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI), while reboxetine is a selective norepinephrine reuptake inhibitor (NaRI). ## Pharmacological Profile Duloxetine works by inhibiting the reuptake of both serotonin and norepinephrine, increasing the availability of these neurotransmitters in the synaptic cleft[6]. It was first approved by the FDA in 2004 for major depressive disorder and has since received approval for various other indications including generalized anxiety disorder, neuropathic pain, and stress incontinence[6][8]. Reboxetine, on the other hand, selectively inhibits norepinephrine reuptake without significantly affecting serotonin or dopamine reuptake[7]. It has been used primarily for the treatment of major depression but has also shown utility in narcolepsy and panic disorders[7]. ## Clinical Evidence A prospective 12-week open-label study assessed the effectiveness of adding reboxetine to 79 depressive outpatients diagnosed with major depressive disorder who had previously not responded, or had responded only partially, to 8 weeks of conventional treatment with duloxetine monotherapy[1]. The results were promising: - Mean Hamilton Depression Rating Scale (HDRS) reduction was 65.5% - 76% of patients were considered responders (≥50% reduction in HDRS) - 69.3% of patients achieved complete remission (HDRS ≤10 points) - 95.8% of patients showed improvement according to Clinical Global Impression-Improvement (CGI-I) scores[1] The combination strategy appears to be particularly valuable for patients with duloxetine-resistant depression[1][2]. In general, combination therapy is considered an alternative to switching strategies in partial responders because it preserves the partial beneficial effects already achieved[2]. ## Safety and Tolerability The most common non-serious adverse events reported with the duloxetine-reboxetine combination include: - Dry mouth - Increased sweating - Constipation - Difficulty passing urine[1] Overall, the combination is generally well-tolerated, with side effects largely related to the individual drugs' profiles[5]. ## Mechanism Considerations The rationale for combining these medications stems from their complementary pharmacological profiles. While duloxetine affects both serotonin and norepinephrine systems, it has a fixed ratio of serotonergic to noradrenergic effects that may limit its therapeutic efficacy in some patients[5]. Adding reboxetine, which primarily affects norepinephrine, may overcome this limitation and produce a different balance of neurotransmitter effects that could be beneficial for treatment-resistant patients[5]. This combination represents one approach among several combination strategies used in managing treatment-resistant depression.